Print

ANRS VAC 14

A phase I clinical to evaluate the safety and immunogenicity at mucosal and systemic levels of oligomeric gp160 with vaginal or nasal administration, with or without adjuvant (DC-Chol) in HIV-1 uninfected women

Trial Details:

I Terminated
French National Agency for Research on AIDS and viral hepatitis (ANRS) June 01, 2003
gp160 MN/LAI Env gp160 B MN/LAI
gp160 MN/LAI Protein
DC-Chol
France 36
http://www.anrs.fr/